The US Food and Drug Administration (FDA) has approved a new drug for the maintenance treatment of opioid use disorder.BioDelivery Sciences International Inc announced in a release that it has received FDA approval of Bunavail (buprenorphine and naloxone) buccal film (CIII) and expects to launch the drug late in the third quarter of 2014.
According to the manufacturer, the drug has a unique adhesive “inside the cheek” delivery system that improves absorption and plasma concentrations of buprenorphine and therefore can be delivered at a lower dose, which may help reduce the potential for misuse and diversion and lessen the incidence of side effects. More.*
*A Medscape account is required to view this article. If you do not have a Medscape account, you can create one for free.
PCSS-O does not endorse any specific commercial product.